Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TRVI, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Nalbuphine | Idiopathic Pulmonary Fibrosis | Phase 3 · NCT07868419 | Recruiting |
| Nalbuphine ER | Prurigo Nodularis | Phase 2/3 · NCT03497975 | Completed |
| Nalbuphine HCL ER | Uremic Pruritus | Phase 2/3 · NCT02143648 | Completed |
| Nalbuphine HCl solution | Nalbuphine | Phase 1 · NCT04018664 | Completed |
Also used in these trials (approved or third-party drugs, not TRVI's own candidates): Nintedanib, Pirfenidone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TRVI holds $299.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $18.6M/quarter from operations, an estimated runway of 48.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 17 · Low
We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into 2030.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TRVI files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| New Enterprise Associates 16, L.P. 10% owner Includes shares also reported by Forest Baskett, counted once |
Insider | 15,074,080 | 10.57% | 2026-05-05 |
| Paul Edward Walker 10% owner |
Insider | 13,222,228 | 9.27% | 2025-12-31 |
| Anthony A. Jr. Florence 10% owner Includes shares also reported by Paul Edward Walker, counted once |
Insider | 13,222,228 | 9.27% | 2025-12-31 |
| Ali Behbahani 10% owner Includes shares also reported by Paul Edward Walker, counted once |
Insider | 13,222,228 | 9.27% | 2025-12-31 |
| Mohamad Makhzoumi 10% owner Includes shares also reported by Paul Edward Walker, counted once |
Insider | 13,222,228 | 9.27% | 2025-12-31 |
| Scott D Sandell 10% owner Includes shares also reported by Paul Edward Walker, counted once |
Insider | 13,222,228 | 9.27% | 2025-12-31 |
| Carmen Chang 10% owner Includes shares also reported by Paul Edward Walker, counted once |
Insider | 13,222,228 | 9.27% | 2025-12-31 |
| FMR LLC | Institution (13G, 5%+) | 12,562,839 | 8.81% | 2026-06-30 |
| Forest Baskett 10% owner |
Insider | 12,273,280 | 8.61% | 2025-12-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 9,779,593 | 6.86% | 2026-09-30 |
| Thomas Sciascia Chief Scientific Officer · +293,000 options |
Insider | 221,373 | 0.16% | 2025-03-25 |
| Jennifer L Good President & CEO, Director · +831,400 options |
Insider | 213,313 | 0.15% | 2025-03-21 |
Share count 142,559,400 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRVI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →